Skip to main content
. Author manuscript; available in PMC: 2016 Feb 1.
Published in final edited form as: Am J Transplant. 2015 Oct 20;16(2):574–582. doi: 10.1111/ajt.13495

Table 3. Multivariable model for natural log–transformed dose-normalized tacrolimus trough concentrations in the discovery cohort.

Variables Effect (95% CI) p-value
For each day after transplant 0.10 (0.08, 0.12) 8.0 × 10−18
Additional effect for each day after day 9 after transplant −0.10 (−0.12, −0.08) 4.2 × 10−17
Age, recipient, years
 18–34 vs. 65–84 −0.35 (−0.70, −0.01) 1.6 × 10−2
 35–64 vs. 65–84 −0.08 (−0.39, 0.23)
GFR center −0.002 (−0.003, 0.000) 1.1 × 10−2
Anti-CMV drug use 0.08 (0.05, 0.12) 6.7 × 10−7
SPK 0.48 (0.15, 0.81) 4.6 × 10−3
Induction immunosuppression
 Combination vs. polyclonal −0.24 (−0.80, 0.32) 7.2 × 10−3
 Monoclonal/IL2RA vs. polyclonal 0.18 (0.03, 0.32)
 None vs. polyclonal 0.63 (0.15, 1.12)

Data are adjusted for enrolling center. CI, confidence interval; CMV, cytomegalovirus; SPK, simultaneous pancreas–kidney.